Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Small Pharma Inc. Small Pharma Reports Fiscal Second Quarter 2024 Highlights October 19, 2023 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT Small Pharma Announces Voting Results from Annual General and Special Meeting of Shareholders October 12, 2023 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder September 26, 2023 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT Small Pharma Reports Fiscal First Quarter 2024 Highlights July 27, 2023 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT Small Pharma Announces SPL028 R&D Strategy Update July 05, 2023 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT Small Pharma Announces Management Team Change July 05, 2023 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights June 28, 2023 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT Small Pharma Announces Significant Developments In Intellectual Property Portfolio May 25, 2023 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology May 03, 2023 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026 April 04, 2023 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT Small Pharma to Host Virtual Roundtable Event with Key Opinion Leaders in Psychiatry March 07, 2023 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy Results March 07, 2023 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT Small Pharma to Present at Cowen’s 43rd Annual Health Care Conference March 01, 2023 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028 February 15, 2023 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue February 01, 2023 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT Small Pharma Reports Fiscal Third Quarter 2023 Highlights January 25, 2023 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder January 25, 2023 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25 January 24, 2023 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026 January 09, 2023 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property December 22, 2022 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT First Patient Dosed in Small Pharma’s Drug Interaction Study December 15, 2022 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT Small Pharma To Support University College London Research Project on Neuroplasticity December 14, 2022 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT Small Pharma to Participate in Upcoming Canaccord Genuity Investor Symposium December 08, 2022 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT Small Pharma to Participate in November Investor and Healthcare Conferences November 11, 2022 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT Small Pharma Receives Approval for First-In-Human Phase I Clinical Trial With SPL028 October 31, 2022 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT Second United States Patent Granted for Small Pharma’s Psychedelics Portfolio October 19, 2022 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT Small Pharma Reports Fiscal Second Quarter 2023 Highlights October 14, 2022 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy With Injectable Formulation July 26, 2022 From Small Pharma Inc. Via GlobeNewswire Tickers DMTTF TSX-V:DMT Small Pharma Inc.: World’s First Clinical Trial For DMT-Assisted Therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I February 22, 2022 From Small Pharma Inc. Via Business Wire Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
